Friday 6-6-2014 Exelixis Inc (EXEL) $EXEL opened a
Post# of 73
Posted On: 06/08/2014 10:13:28 PM
Friday 6-6-2014 Exelixis Inc (EXEL) $EXEL opened at 3.37 hitting the high price of 3.37 and a day low of 3.26 with a total volume of 1,661,200. EXEL had a previous close of 3.28 and has been seeing an average volume of 2,089,690.
Overall Average: 56% Sell
Recent stock forum discussions about EXEL http://investorshangout.com/search?q=EXEL&...mp;yt0=Go!
Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10
Business Wire - Tue Jun 03, 3:15PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Goldman Sachs 35th Annual Global Healthcare Conference taking place next week in Rancho Palos Verdes, California. The Exelixis presentation is scheduled for 12:20 p.m. EDT/9:20 a.m. PDT on Tuesday, June 10, 2014. (full story)
Why Wall Street Hates Exelixis Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 9:18AM CDT
Stocks with a high short interest can signal that something is fundamentally wrong with the underlying company. By the same token, short-sellers aren't always correct in their assessment of a company, and their mistakes can lead to a rapid upward... (full story)
Technical Coverage on Health Care Sector Equities -- Research on Arena Pharma, Exelixis, Dendreon, and Seattle Genetics
PR Newswire - Fri May 30, 6:40AM CDT
The trading session on Thursday, May 29, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,698.74, up 0.39% and the NASDAQ Composite closed at 4,247.95, up 0.54%. The S&P 500 finished the day 0.54% higher at 1,920.03. The gains were broad based as nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index closed the day at 688.45, up 0.76%, and the index has advanced 2.45% in the previous one month. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Exelixis Inc. (NASDAQ: EXEL), Dendreon Corp. (NASDAQ: DNDN) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on ARNA, EXEL, DNDN and SGEN can be downloaded upon signing up at: (full story)
Better Bad News Buy: Ariad Pharmaceuticals vs. Exelixis
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 23, 5:30PM CDT
Ariad Pharmaceuticals and Exelixis have both stumbled, with bad news causing significant drops in share price over the past year (Ariad has lost over 60% of its value, while Exelixis is down 30% over the last year and over 60% from its 52-week... (full story)
Circulating Tumor Cells and Cancer Stem Cells Technologies - Global Strategic Business Report 2014
M2 - Mon May 19, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vwbmb9/circulating_tumor) has announced the addition of the "Circulating Tumor Cells and Cancer Stem Cells Technologies - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Circulating Tumor Cells and Cancer Stem Cells Technologies in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered: Click the link below to view the full, extended table of contents. I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. CIRCULATING TUMOR CELLS (CTCS) GLOBAL MARKET OVERVIEW - Real-Time Liquid Biopsy' Scores Over Surgical Biopsy - Challenges in CTC Diagnostics - Need for CTC Enrichment and Popular Methods 2. MARKET TRENDS AND DRIVERS - CTCs for Personalized Cancer Treatment - Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis - CTC Microdevices Hog the Limelight 3. CANCER STEM CELLS GLOBAL MARKET OVERVIEW - CSC-Focused Innovations in Cancer Therapeutics - Select Pathways or Molecular Targets for CSC Candidates - Pipeline Analysis of Select Cancer Stem Cells Therapeutics ( 2014) 4. CTC AND CSC RESEARCH FINDINGS & BREAKTHROUGHS - Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity - NBiomics Makes its Contribution to CTC Diagnosis - Researchers at University of Michigan Develop Revolutionary Capture CTCs Method 5. MEDICAL DIAGNOSTICS MARKET A CONCEPTUAL OVERVIEW - Molecular Diagnostics for Lymphoid Malignancies - Market Trends & Issues - Global Molecular Diagnostics on a High Growth Curve - Automation Driving Global Market - Molecular Diagnostics: Marking Convergence of Numerous Technologies 6. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS ENRICHMENT, IDENTIFICATION AND CHARACTERIZATION METHODS - Filtration (iSET) - Density Gradient - Immuno-magnetic Cell Enrichment - Advantages of Different CTC Enrichment Procedures - AdnaTest 7. CANCER STEM CELLS (CSCS) BIOLOGY, ISOLATION, CSC SURFACE MARKERS, AND SIGNALING PATHWAYS - Differences between Normal Stem Cells and Cancer Stem Cells - Hierarchical versus Stochastic Models of Tumour Cell Heterogeneity - Isolation of Cancer Stem Cells - Characteristics of Cancer Stem Cells - Resistance to Chemotherapy - Resistance to Radiation - Invasion or Metastatic Activity 8. PRODUCT LAUNCHES AND INTRODUCTIONS - EU Authorisation for ANGLE's Parsortix Cancer Diagnostic Device - ANGLE Launches Parsortix Device into the Research Market - Promab Introduces New Range of Cancer Stem Cells Solutions - Clearbridge BioMedics Unveils ClearCell? FX Cancer Cell Enrichment System - Fluxion Introduces New IsoFlux System CTC Technology - Cynvenio Launches LiquidBiopsy Lab Service - Biocept Launches OncoCEE-BR - ApoCell to Launch ApoStream 9. RECENT INDUSTRY ACTIVITY - Stem Cell Therapeutics and University of York Ink Option Agreement - Veridex Undergoes Name Change to Janssen Diagnostics - Janssen Diagnostics and Arno Therapeutics Ink Collaboration Agreement - Veridex Enters into Agreement with LabCorp - Stemline Therapeutics Obtains Orphan Drug Designation for SL-401 10. FOCUS ON SELECT MAJOR PLAYERS IN CTC DIAGNOSTICS - Adnagen GmbH (Germany) - ApoCell, Inc (US) - Biocep LTD (Israel) - Biocept, Inc. (US) - Biofluidica Microtechnologies LLC (US) - Celltrafix Inc. (US) - Clearbridge Biomedics (Singapore) - Creatv Microtech, Inc (US) - Cynvenio Biosystems, Inc. (US) - Ikonisys, Inc. (US) - IVDiagnostics, Inc. (US) - Janssen Diagnostics LLC (US) - Epic Biosciences Inc (US) - RARECELLS SAS (Italy) - SCREENCELL (France) - Stemcell Technologies, Inc. (Canada) 11. SELECT MARKET PARTICIPANTS IN THE CANCER STEM CELLS (CSCS) SPACE - Alchemia Limited (Australia) - Amgen Inc. (US) - Exelixis, Inc. (US) - Formula Pharmaceuticals (US) - GlaxoSmithKline Plc. (UK) - Geron Corp. (US) - Infinity Pharmaceuticals (US) - Kalobios Pharmaceuticals Inc. (US) - Novartis AG (Switzerland) - OncoMed Pharmaceuticals, Inc. (US) - Pfizer, Inc. (US) - Roche Diagnostics (Switzerland) - Verastem, Inc. (US) 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 66 (including Divisions/Subsidiaries 67) - The United States (46) - Canada (3) - Japan (2) - Europe (9) - France (3) - Germany (2) - The United Kingdom (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (4) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/vw...ting_tumor (full story)
'Mad Money' Lightning Round: I Believe in Hewlett-Packard
at The Street - Sat May 17, 5:00AM CDT
Cramer is sticking with Wendy's but he thinks Exelixis is too risky. (full story)
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 16, 7:13PM CDT
Next week will be big for retailer earnings, Cramer says. (full story)
Cabozantinib and Cobimetinib to Be Featured in Ten Presentations at 2014 ASCO Annual Meeting
Business Wire - Wed May 14, 4:33PM CDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that cabozantinib and cobimetinib will be the subject of ten presentations at the upcoming 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, which will be held May 30 to June 3, 2014 in Chicago, Illinois, is expected to draw more than 25,000 oncology professionals from around the world. (full story)
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory (full story)
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic (full story)
Medullary Thyroid Cancer - Pipeline Review, H1 2014
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/htrmtc/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Medullary Thyroid Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Medullary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - AstraZeneca PLC - Novartis AG - Exelixis, Inc. - Ariad Pharmaceuticals, Inc. - OXiGENE, Inc. - Nerviano Medical Sciences S.r.l. - Globeimmune, Inc. - Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...ry_thyroid (full story)
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria (full story)
Exelixis Announces Presentation of Final Phase 1b Data for Cobimetinib in Combination with Vemurafenib at EADO Congress 2014
Business Wire - Wed May 07, 12:00AM CDT
--- 87% confirmed Overall Response Rate, 13.7-month median Progression Free Survival and 83% 1 year survival estimate for the combination in BRAFi-naive patients observed in exploratory analyses of anti-tumor activity - (full story)
Exelixis to Present at Two Investor Conferences in May
Business Wire - Tue May 06, 3:19PM CDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the following two investor conferences in May: (full story)
Technical Data on Biotech Stocks -- Research on Exact Sciences, Amgen, Exelixis, and Incyte
PR Newswire - Tue May 06, 8:57AM CDT
On Monday, May 05, 2014, the NASDAQ Composite ended at 4,138.06, up 0.34%, the Dow Jones Industrial Average finished the day 0.11% higher at 16,530.55, and the S&P 500 closed at 1,884.66, up 0.19%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, and the index has advanced 0.12% in the last one month. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), Amgen Inc (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL) and Incyte Corp. Ltd (NASDAQ: INCY). Free technical research on EXAS, AMGN, EXEL and INCY can be downloaded upon signing up at: (full story)
Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 6:25PM CDT
A lot of hope is resting on Exelixis ' Cometriq as a possible treatment for metastatic castration-resistant prostate cancer; but tonight was all about the company's first-quarter earnings results . For the quarter, the cancer-focused drug... (full story)
Exelixis Announces First Quarter 2014 Financial Results
Business Wire - Thu May 01, 3:13PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended March 31, 2014. (full story)
Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:01AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exelixis , Geron , and Vertex Pharmaceuticals today. Exelixis set to release first quarter results today Normally, earnings season for... (full story)
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic (full story)
Overall Average: 56% Sell
Recent stock forum discussions about EXEL http://investorshangout.com/search?q=EXEL&...mp;yt0=Go!
Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10
Business Wire - Tue Jun 03, 3:15PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Goldman Sachs 35th Annual Global Healthcare Conference taking place next week in Rancho Palos Verdes, California. The Exelixis presentation is scheduled for 12:20 p.m. EDT/9:20 a.m. PDT on Tuesday, June 10, 2014. (full story)
Why Wall Street Hates Exelixis Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 9:18AM CDT
Stocks with a high short interest can signal that something is fundamentally wrong with the underlying company. By the same token, short-sellers aren't always correct in their assessment of a company, and their mistakes can lead to a rapid upward... (full story)
Technical Coverage on Health Care Sector Equities -- Research on Arena Pharma, Exelixis, Dendreon, and Seattle Genetics
PR Newswire - Fri May 30, 6:40AM CDT
The trading session on Thursday, May 29, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,698.74, up 0.39% and the NASDAQ Composite closed at 4,247.95, up 0.54%. The S&P 500 finished the day 0.54% higher at 1,920.03. The gains were broad based as nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index closed the day at 688.45, up 0.76%, and the index has advanced 2.45% in the previous one month. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Exelixis Inc. (NASDAQ: EXEL), Dendreon Corp. (NASDAQ: DNDN) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on ARNA, EXEL, DNDN and SGEN can be downloaded upon signing up at: (full story)
Better Bad News Buy: Ariad Pharmaceuticals vs. Exelixis
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 23, 5:30PM CDT
Ariad Pharmaceuticals and Exelixis have both stumbled, with bad news causing significant drops in share price over the past year (Ariad has lost over 60% of its value, while Exelixis is down 30% over the last year and over 60% from its 52-week... (full story)
Circulating Tumor Cells and Cancer Stem Cells Technologies - Global Strategic Business Report 2014
M2 - Mon May 19, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vwbmb9/circulating_tumor) has announced the addition of the "Circulating Tumor Cells and Cancer Stem Cells Technologies - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Circulating Tumor Cells and Cancer Stem Cells Technologies in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered: Click the link below to view the full, extended table of contents. I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. CIRCULATING TUMOR CELLS (CTCS) GLOBAL MARKET OVERVIEW - Real-Time Liquid Biopsy' Scores Over Surgical Biopsy - Challenges in CTC Diagnostics - Need for CTC Enrichment and Popular Methods 2. MARKET TRENDS AND DRIVERS - CTCs for Personalized Cancer Treatment - Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis - CTC Microdevices Hog the Limelight 3. CANCER STEM CELLS GLOBAL MARKET OVERVIEW - CSC-Focused Innovations in Cancer Therapeutics - Select Pathways or Molecular Targets for CSC Candidates - Pipeline Analysis of Select Cancer Stem Cells Therapeutics ( 2014) 4. CTC AND CSC RESEARCH FINDINGS & BREAKTHROUGHS - Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity - NBiomics Makes its Contribution to CTC Diagnosis - Researchers at University of Michigan Develop Revolutionary Capture CTCs Method 5. MEDICAL DIAGNOSTICS MARKET A CONCEPTUAL OVERVIEW - Molecular Diagnostics for Lymphoid Malignancies - Market Trends & Issues - Global Molecular Diagnostics on a High Growth Curve - Automation Driving Global Market - Molecular Diagnostics: Marking Convergence of Numerous Technologies 6. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS ENRICHMENT, IDENTIFICATION AND CHARACTERIZATION METHODS - Filtration (iSET) - Density Gradient - Immuno-magnetic Cell Enrichment - Advantages of Different CTC Enrichment Procedures - AdnaTest 7. CANCER STEM CELLS (CSCS) BIOLOGY, ISOLATION, CSC SURFACE MARKERS, AND SIGNALING PATHWAYS - Differences between Normal Stem Cells and Cancer Stem Cells - Hierarchical versus Stochastic Models of Tumour Cell Heterogeneity - Isolation of Cancer Stem Cells - Characteristics of Cancer Stem Cells - Resistance to Chemotherapy - Resistance to Radiation - Invasion or Metastatic Activity 8. PRODUCT LAUNCHES AND INTRODUCTIONS - EU Authorisation for ANGLE's Parsortix Cancer Diagnostic Device - ANGLE Launches Parsortix Device into the Research Market - Promab Introduces New Range of Cancer Stem Cells Solutions - Clearbridge BioMedics Unveils ClearCell? FX Cancer Cell Enrichment System - Fluxion Introduces New IsoFlux System CTC Technology - Cynvenio Launches LiquidBiopsy Lab Service - Biocept Launches OncoCEE-BR - ApoCell to Launch ApoStream 9. RECENT INDUSTRY ACTIVITY - Stem Cell Therapeutics and University of York Ink Option Agreement - Veridex Undergoes Name Change to Janssen Diagnostics - Janssen Diagnostics and Arno Therapeutics Ink Collaboration Agreement - Veridex Enters into Agreement with LabCorp - Stemline Therapeutics Obtains Orphan Drug Designation for SL-401 10. FOCUS ON SELECT MAJOR PLAYERS IN CTC DIAGNOSTICS - Adnagen GmbH (Germany) - ApoCell, Inc (US) - Biocep LTD (Israel) - Biocept, Inc. (US) - Biofluidica Microtechnologies LLC (US) - Celltrafix Inc. (US) - Clearbridge Biomedics (Singapore) - Creatv Microtech, Inc (US) - Cynvenio Biosystems, Inc. (US) - Ikonisys, Inc. (US) - IVDiagnostics, Inc. (US) - Janssen Diagnostics LLC (US) - Epic Biosciences Inc (US) - RARECELLS SAS (Italy) - SCREENCELL (France) - Stemcell Technologies, Inc. (Canada) 11. SELECT MARKET PARTICIPANTS IN THE CANCER STEM CELLS (CSCS) SPACE - Alchemia Limited (Australia) - Amgen Inc. (US) - Exelixis, Inc. (US) - Formula Pharmaceuticals (US) - GlaxoSmithKline Plc. (UK) - Geron Corp. (US) - Infinity Pharmaceuticals (US) - Kalobios Pharmaceuticals Inc. (US) - Novartis AG (Switzerland) - OncoMed Pharmaceuticals, Inc. (US) - Pfizer, Inc. (US) - Roche Diagnostics (Switzerland) - Verastem, Inc. (US) 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 66 (including Divisions/Subsidiaries 67) - The United States (46) - Canada (3) - Japan (2) - Europe (9) - France (3) - Germany (2) - The United Kingdom (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (4) - Middle East (3) For more information visit http://www.researchandmarkets.com/research/vw...ting_tumor (full story)
'Mad Money' Lightning Round: I Believe in Hewlett-Packard
at The Street - Sat May 17, 5:00AM CDT
Cramer is sticking with Wendy's but he thinks Exelixis is too risky. (full story)
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 16, 7:13PM CDT
Next week will be big for retailer earnings, Cramer says. (full story)
Cabozantinib and Cobimetinib to Be Featured in Ten Presentations at 2014 ASCO Annual Meeting
Business Wire - Wed May 14, 4:33PM CDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that cabozantinib and cobimetinib will be the subject of ten presentations at the upcoming 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, which will be held May 30 to June 3, 2014 in Chicago, Illinois, is expected to draw more than 25,000 oncology professionals from around the world. (full story)
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory (full story)
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic (full story)
Medullary Thyroid Cancer - Pipeline Review, H1 2014
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/htrmtc/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Medullary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medullary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Medullary Thyroid Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Medullary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Medullary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - AstraZeneca PLC - Novartis AG - Exelixis, Inc. - Ariad Pharmaceuticals, Inc. - OXiGENE, Inc. - Nerviano Medical Sciences S.r.l. - Globeimmune, Inc. - Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...ry_thyroid (full story)
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria (full story)
Exelixis Announces Presentation of Final Phase 1b Data for Cobimetinib in Combination with Vemurafenib at EADO Congress 2014
Business Wire - Wed May 07, 12:00AM CDT
--- 87% confirmed Overall Response Rate, 13.7-month median Progression Free Survival and 83% 1 year survival estimate for the combination in BRAFi-naive patients observed in exploratory analyses of anti-tumor activity - (full story)
Exelixis to Present at Two Investor Conferences in May
Business Wire - Tue May 06, 3:19PM CDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the following two investor conferences in May: (full story)
Technical Data on Biotech Stocks -- Research on Exact Sciences, Amgen, Exelixis, and Incyte
PR Newswire - Tue May 06, 8:57AM CDT
On Monday, May 05, 2014, the NASDAQ Composite ended at 4,138.06, up 0.34%, the Dow Jones Industrial Average finished the day 0.11% higher at 16,530.55, and the S&P 500 closed at 1,884.66, up 0.19%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, and the index has advanced 0.12% in the last one month. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), Amgen Inc (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL) and Incyte Corp. Ltd (NASDAQ: INCY). Free technical research on EXAS, AMGN, EXEL and INCY can be downloaded upon signing up at: (full story)
Exelixis' Q1 Loss Widens 67% on Higher Trial and Personnel Costs
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 6:25PM CDT
A lot of hope is resting on Exelixis ' Cometriq as a possible treatment for metastatic castration-resistant prostate cancer; but tonight was all about the company's first-quarter earnings results . For the quarter, the cancer-focused drug... (full story)
Exelixis Announces First Quarter 2014 Financial Results
Business Wire - Thu May 01, 3:13PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended March 31, 2014. (full story)
Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:01AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exelixis , Geron , and Vertex Pharmaceuticals today. Exelixis set to release first quarter results today Normally, earnings season for... (full story)
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic (full story)
(0)
(0)Exelixis Inc. (EXEL) Stock Research Links
Scroll down for more posts ▼